--Sole Source Contract of Vaccinia Immune Globulin Intravenous (VIGIV)

The U.S. Army Space and Missile Defense Command on behalf of the Joint Vaccine Acquisition Program intends to procure on a sole source basis a commercial, FDA-licensed Vaccinia Immune Globulin Intraveous (VIGIV) to treat severe reactions to smallpox vaccinations. The intended source is Cangene Corporation, 104 Chancellor Matheson Road, Winnipeg, Manitoba, Canada. It is anticipated a contract will be issued for a one year base period and 6 options periods. This contract will be issued using other than full and open competition procedures in accordance with FAR 6.3 and 10 U.S.C. 2304(c)(1), only one responsible source and no other supplies or services will satisfy agency requirements. Cangene Corporation is the only know FDA license holder for VIGIV whi ch currently has the manufacturing capability to maintain the Department of Defense's (DoD's) requirement for a stockpile of 400 Troop Equivalent Doses (TED). This is not a request for competitive proposals but parties purporting to have the requisite cred entials to furnish these supplies must provide in writing, factual information which clearly supports and demonstrates that their VIGIV product is FDA approved, has an existing approved manufacturing facility, as well as the capability to maintain their ma nufacturing facility and FDA license so the DoD will have a continuous stockpile of licenses VIGIV. This information MUST be emailed to [email protected] or faxed to her attention at (301)619-5069 by no later than 4:00 p.m. on 8 August 2006 . A determination not to compete this proposed action based on any response to this notice is solely within the discretion of the contracting officer.